Results 61 to 70 of about 1,098,931 (194)

Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors

, 2023
PURPOSE OF REVIEW: To provide a detailed overview of cardiovascular adverse events associated with the use of tyrosine kinase inhibitors across different tumor types. RECENT FINDINGS: Despite an undeniable survival advantage of tyrosine kinase inhibitors
Cortes, Jorge, Raval, Girindra, Guha, Avirup, Addison, Daniel, Sayegh, Nicolas, Agarwal, Neeraj, Weintraub, Neal L, Sayed, Nazish, Fradley, Michael, Yirerong, Juliet   +9 more
core   +1 more source

Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study

British Journal of Haematology, EarlyView.
Summary While marginal zone lymphoma (MZL) is generally indolent, outcomes following relapse remain poorly defined. This study utilized the indolent Non Follicular 10 (NF10) prospective database to characterize survival and identify prognostic drivers in patients failing initial systemic therapy. The study analysed 122 patients with relapsed MZL.
Stefano Luminari, Maria Elena Nizzoli, Michele Merli, Sara Rattotti, Vittoria Tarantino, Simone Ferrero, Annalisa Talami, Roberta Murru, Marina Deodato, Emanuele Cencini, Giovanni Roti, Carlo Visco, Guilherme Duffles, Michele Spina, Ombretta Annibali, Alessandro Pulsoni, Andrés José María Ferreri, Caterina Stelitano, Elsa Pennese, Emiliano Barbieri, Marzia Varettoni, Gambara Silvia, Marta Coscia, Dario Marino, Tisi Maria Chiara, Maher Nawar, Luigi Marcheselli, Francesco Merli, Luca Arcaini   +28 more
wiley   +1 more source

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia [PDF]

, 2013
Purpose: Aberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy resistance in various malignancies including leukemias. In Philadelphia chromosome (Ph) positive leukemias, activation of PI3K by dysregulated BCR-ABL tyrosine kinase ...
Oliver G Ottmann, Martin Ruthardt, Oliver G. Ottmann, Oliver G. Ottmann (485229), Falkenburg, J.H.F., Marcus Liebermann (485228), Bart A. Nijmeijer (485227), Pfeifer, Heike, Falkenburg, J. H. Frederik, J. H. Frederik Falkenburg, Ruthardt, Martin, Tamara Tesanovic, Tesanovic, Tamara, Bart A Nijmeijer, Heike Pfeifer, Ottmann, Oliver G., Susanne Badura (485223), Sylvia Wystub, Sylvia Wystub (485226), Liebermann, M., Marcus Liebermann, Bart A. Nijmeijer, Ottmann, O.G., Nijmeijer, Bart A., Badura, S., Susanne Badura, Wystub, Sylvia, Pfeifer, H., J H Frederik Falkenburg, Tamara Tesanovic (485224), Martin Ruthardt (66634), Wystub, S., Nijmeijer, B.A., Ruthardt, M., Tesanovic, T., Badura, Susanne, Heike Pfeifer (485225), J. H. Frederik Falkenburg (210432), Liebermann, Marcus   +38 more
core   +1 more source

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

British Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb   +45 more
wiley   +1 more source

PKD1 3D Structure Model and Docking Studies for New PKD Inhibitors [PDF]

, 2013
Protein kinase Ds (PKDs) are diacylglycerol (DAG)-regulated serine/threonine protein kinases. In intact cells, PKDs are key mediators in cellular processes pertaining to multiple diseases, including cancer, heart diseases, angiogenesis and immune ...
Xu, Qi
core  

Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms

, 2015
Targeting tyrosine kinases represents a highly specific treatment approach for different malignancies. This also includes non-Hodgkin lymphoma since it is well known that these enzymes are frequently involved in the lymphomagenesis.
Thomas K. Held, Reinhard Marks, Nadine Kutsch, Martin Schmidt-Hieber, Richard Ratei   +4 more
core   +1 more source

Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)

Advances in Hematology, 2022
Of the variety of immunoglobulin related amyloidosis (AL), immunoglobulin M (IgM) related AL represents only 6 to 10% of affected patients, and the majority of these cases are associated with underlying non-Hodgkin’s Lymphoma including Waldenström’s ...
Maroun Bou Zerdan, Jason Valent, Maria Julia Diacovo, Karl Theil, Chakra P. Chaulagain   +4 more
doaj   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?

ImmunoTargets and Therapy, 2020
Ana Lorenzo-Vizcaya,1 Serena Fasano,2 David A Isenberg3 1Department of Internal Medicine, Hospital Universitario De Ourense, Ourense, Spain; 2Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Campania L.
Lorenzo-Vizcaya A, Fasano S, Isenberg DA
doaj  

Cancer biomarkers for targeted therapy

Biomarker Research, 2019
Tumor-associated antigens (TAA) or cancer biomarkers are major targets for cancer therapies. Antibody- based agents targeting the cancer biomarkers include monoclonal antibodies (MoAbs), radiolabeled MoAbs, bispecific T cell engagers, and antibody-drug ...
Delong Liu
doaj   +1 more source